WUXI XDC
LIVE

Serial Number

98069930

Owner

WuXi XDC Cayman Inc.

Attorney

Eric Lamb

First Use Date

Mar 9, 2023

Filing Date

Jul 3, 2023

Add to watchlist:

No watchlists yet
View on USPTO

WUXI XDC Trademark

Serial Number: 98069930 • Registration: 7763179

WUXI XDC is a trademark filed by WuXi XDC Cayman Inc. on July 3, 2023. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

WuXi XDC Cayman Inc. (15 trademarks)

No.11, Xinhui Ring Road
Wuxi, Jiangsu Province 214028 , CN

Entity Type: 03

Trademark Details

Filing Date

July 3, 2023

Registration Date

April 15, 2025

First Use Anywhere

March 9, 2023

First Use in Commerce

March 9, 2023

Published for Opposition

December 5, 2023

Goods & Services

Custom assembling of materials for others; custom manufacturing of pharmaceuticals; custom manufacturing of drug conjugates; custom production of pharmaceuticals; custom production of biological preparations; custom manufacturing of Antibody-drug Conjugates; custom manufacturing of chemical reagents; custom manufacturing of pharmaceutical preparations; custom manufacturing of biomedical preparations; custom manufacture of drug conjugates; processing of pharmaceutical preparations; processing or treating of chemical reagents; processing of antibody drugs; custom manufacturing of Antibody drugs; processing of biomedical preparations; processing of biotechnology drug

Development of products for others in the field of pharmaceuticals; pharmaceutical drug development services; research and development of new products in the field of pharmaceuticals; biochemical research and development; custom design and development of chemical reagent antibodies and conjugate antibodies; research and development in the pharmaceutical, biomedicine and biotechnology fields; research and development of antibodies; research and development of conjugated antibodies; biomedical research services; development of pharmaceutical preparations and medicines; research and development of antibody-drug conjugates; research and development of drug conjugates; preclinical research and evaluation of new drugs; consulting services in the field of technology development; research and development of new products for others; scientific research and development

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 15, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 15, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 25, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 25, 2025 CNPR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 21, 2025 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Feb 20, 2025 SUPC
SOU EXTENSION 2 GRANTED
Feb 20, 2025 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 20, 2025 AITU
USE AMENDMENT FILED
Dec 8, 2024 IUAF
SOU EXTENSION 2 FILED
Dec 8, 2024 EXT2
TEAS STATEMENT OF USE RECEIVED
Dec 8, 2024 EISU
SOU TEAS EXTENSION RECEIVED
Dec 8, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 24, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jul 18, 2024 EX1G
SOU EXTENSION 1 FILED
Jul 18, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 18, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 30, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 5, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 5, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 15, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 1, 2023 CNSA
ASSIGNED TO EXAMINER
Oct 31, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 4, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 3, 2023 NWOS
NEW APPLICATION ENTERED
Jul 6, 2023 NWAP